Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:LIXT NASDAQ:MDCX NASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.97+6.8%$2.35$1.60▼$4.94$112.59M3.251.21 million shs1.15 million shsLIXTLixte Biotechnology$7.08-7.7%$5.89$2.02▼$8.38$106.36M1.23149,305 shs503,962 shsMDCXMedicus Pharma$0.42+3.8%$0.35$0.25▼$3.69$23.51M-0.063.93 million shs652,784 shsTHARTharimmune$2.94+4.3%$3.13$0.95▼$9.08$110.93M1.431.48 million shs310,005 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-0.54%-1.08%-18.58%-23.01%-25.81%LIXTLixte Biotechnology+3.37%+11.64%+6.38%+151.48%+550.00%MDCXMedicus Pharma-10.37%-5.95%+14.84%-10.51%-86.44%THARTharimmune+1.44%-12.69%-9.03%-12.96%+58.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.97+6.8%$2.35$1.60▼$4.94$112.59M3.251.21 million shs1.15 million shsLIXTLixte Biotechnology$7.08-7.7%$5.89$2.02▼$8.38$106.36M1.23149,305 shs503,962 shsMDCXMedicus Pharma$0.42+3.8%$0.35$0.25▼$3.69$23.51M-0.063.93 million shs652,784 shsTHARTharimmune$2.94+4.3%$3.13$0.95▼$9.08$110.93M1.431.48 million shs310,005 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-0.54%-1.08%-18.58%-23.01%-25.81%LIXTLixte Biotechnology+3.37%+11.64%+6.38%+151.48%+550.00%MDCXMedicus Pharma-10.37%-5.95%+14.84%-10.51%-86.44%THARTharimmune+1.44%-12.69%-9.03%-12.96%+58.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$9.83398.14% UpsideLIXTLixte Biotechnology 1.00SellN/AN/AMDCXMedicus Pharma 2.25Hold$9.002,073.91% UpsideTHARTharimmune 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MDCX, THAR, LIXT, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/21/2026MDCXMedicus Pharma Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 7/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.62$0.56 per share3.51$1.97 per share1.00LIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/AMDCXMedicus PharmaN/AN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)LIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/AMDCXMedicus Pharma-$35.46M-$2.68N/AN/AN/AN/A-3,137.84%-311.33%8/10/2026 (Estimated)THARTharimmune-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/ALatest MDCX, THAR, LIXT, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/A5/14/2026Q1 2026MDCXMedicus Pharma-$0.18-$0.31-$0.13-$0.31N/AN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46LIXTLixte BiotechnologyN/A2.782.78MDCXMedicus PharmaN/A1.221.22THARTharimmuneN/A4.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%LIXTLixte Biotechnology5.10%MDCXMedicus PharmaN/ATHARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%LIXTLixte Biotechnology9.50%MDCXMedicus Pharma8.10%THARTharimmune6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableLIXTLixte Biotechnology415.02 million13.59 millionNot OptionableMDCXMedicus PharmaN/A56.66 million52.07 millionN/ATHARTharimmune237.73 million35.20 millionNot OptionableMDCX, THAR, LIXT, and BDTX HeadlinesRecent News About These CompaniesTharimmune Inc.May 13, 2026 | wsj.comTharimmune Rebrands as Canton Strategic Holdings, Updates TickerFebruary 18, 2026 | tipranks.comIs Canton’s price set to explode amid Tharimmune’s rebrand?February 17, 2026 | invezz.comITharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyFebruary 17, 2026 | prnewswire.comCatherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio ImpactFebruary 11, 2026 | finance.yahoo.comTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerFebruary 6, 2026 | prnewswire.comTharimmune Elects Jill Sommers and William Wiley to Board of DirectorsFebruary 2, 2026 | prnewswire.comTharimmune Approved as Super Validator on Canton NetworkJanuary 27, 2026 | theglobeandmail.comTharimmune Announces Expanded Role as Super Validator on Canton NetworkJanuary 26, 2026 | prnewswire.comTharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On TokenizationJanuary 23, 2026 | seekingalpha.comTharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct OfferingJanuary 22, 2026 | prnewswire.comTharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered OfferingJanuary 20, 2026 | prnewswire.comTharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton NetworkDecember 18, 2025 | prnewswire.comTharimmune appoints Jacob Asbury as CFODecember 12, 2025 | msn.comTharimmune Appoints Jacob Asbury as New CFODecember 12, 2025 | tipranks.comTharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury StrategyDecember 12, 2025 | businesswire.comTharimmune files to sell 176.93M shares of common stock for holdersDecember 5, 2025 | msn.comCrypto Company Creates Bizarre DrugNovember 22, 2025 | msn.comTharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?November 22, 2025 | defenseworld.netDDigital Assets Firm Copper Serves as Custodian for Tharimmune, Inc. Canton Coin Treasury StrategyNovember 19, 2025 | crowdfundinsider.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDCX, THAR, LIXT, and BDTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.96 +0.12 (+6.25%) As of 03:10 PM Eastern This is a fair market value price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Lixte Biotechnology NASDAQ:LIXT$7.06 -0.61 (-7.89%) As of 03:10 PM Eastern This is a fair market value price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Medicus Pharma NASDAQ:MDCX$0.42 +0.02 (+3.75%) As of 03:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Tharimmune NASDAQ:THAR$2.94 +0.12 (+4.26%) As of 07/1/2026Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Shorting the Grid: Bloom Energy’s $25B AI Power Play SMRs Spark a Chain Reaction for Nano Nuclear 3 Dividend ETFs Built for Stability in a Volatile Market Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI Netflix Stock Is Near 2021 Levels, and Bulls See 4 Reasons to Care General Mills Is a 5-Star Turnaround Play for Buy and Hold Investors Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
